CME: Emerging Considerations in Triple-Negative Breast Cancer: Focus on Immunotherapy

Advancements in Treatment Approaches for Triple-Negative Breast Cancer

Advancements in Treatment Approaches for Triple-Negative Breast Cancer
RestartResume
Could immunotherapy-based combination therapy approaches change the standard of care for patients with triple-negative breast cancer?

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Triple-negative breast cancer (TNBC) is an aggressive malignancy of breast cancer, and a diagnosis of this disease presents significant therapeutic challenges, including low survival rates and minimal treatment options. But thanks to the advancement of genomic technologies and continuing study developments, the standard of care for TNBC could be changing…

      

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:  
    Tiffany Traina, MD
    Associate Attending Physician
    Breast Medicine Service at Memorial Sloan Kettering Cancer Center
    New York, NY

    Consulting Fees: Aduro Biotech, Advaxis, AstraZeneca, Athenex, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Genentech/Roche, Genomic Health, Halozyme, Innocrin Pharma, Merck, Pfizer, Puma Biotechnology, Roche/Genentech Samsung
    Research Funding: Astellas Pharms, AstraZeneca, Carrick Pharm, Daiichi Sankyo, Eisai, Genentech/Roche, Immunomedics, Innocrin Pharma, Novartis, Pfizer

    Sara Hurvitz, MD
    Associate Professor of Medicine
    UCLA
    Los Angeles, CA

    Contracted Research: Ambrx, Amgen, Bayer, Boerenger Ingelheim, Daiichi Sankyo, Genentech, GSK, Immunomedics, Lilly, Macrogenics, Novartis, Pfizer, Pieris, Puma, Roche, Sanofi, Seattle Genetics

    Reviewers/Content Planners/Authors:

    • Ann Early has nothing to disclose.
    • Ashley Pluta has nothing to disclose.
    • Nick Lombardi has ownership interest with Vertex Pharmaceuticals.
    • Jennifer Caudle, DO has nothing to disclose.
    • William Mencia, MD, FACEHP, CHCP has nothing to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe unmet needs, molecular heterogeneity of TNBC, and current challenges in its targeted treatment and management.
    • Discuss new insights into the pathobiology of TNBC, including the role of TILs, PD-1, PD-L1, and how these could be harnessed for therapy.
    • Evaluate the utility of recent data from clinical trials in identifying subsets of patients with TNBC for immunotherapy treatment approaches to achieve better outcomes in the first-line setting.
  • Target Audience

    This activity is designed to meet the educational needs of practicing oncologists.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative (GLC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    GLC designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

     

  • Commercial Support

    This activity is supported by an independent educational grant from Genentech, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

Facebook Comments

Sign up for the Prova Education newsletters.

Better education for a better you.

* Required
Optional
Register

We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free